Adocia: final dose in phase 3 trial

(CercleFinance.com) - Adocia announces the administration of the last dose to the last patient with Type 2 diabetes in a Phase 3 clinical trial evaluating BioChaperone Lispro, the company's innovative ultra-fast insulin.


This administration concludes the study in question, and is associated with a $10 million payment from Tonghua Dongbao to Adocia. Phase 3 primary results are expected in the first half of 2025.

"The granting of marketing authorization will trigger an additional milestone payment of $20 million, followed by double-digit royalties on sales", the biopharmaceutical company also points out.

Copyright (c) 2024 CercleFinance.com. All rights reserved.